First-Generation Drug-Eluting Stents for Chronic Total Occlusion

Biodegradable polymer drug-eluting stents versus first-generation durable polymer drug-eluting stents

BACKGROUND Even if drug-eluting stents (DES) showed beneficial effects in patients with coronary artery diseases (CADs), limitations have been observed with the first-generation durable polymer DES (DP-DES). Recently, biodegradable polymer DES (BP-DES) have been approved to be used as an alternative to DP-DES, with potential benefits. We aimed to systematically compare BP-DES with the first-gen...

First-Generation Versus Second-Generation Drug-Eluting Stents in Coronary Chronic Total Occlusions: Two-Year Results of a Multicenter Registry

BACKGROUND Limited data are available regarding the long-term clinical outcomes of second-generation drug-eluting stents (DES) versus first-generation DES in patients with coronary chronic total occlusion (CTO) who undergo percutaneous coronary intervention (PCI). The aim of this study was to compare the clinical outcomes of second-generation DES with those of first-generation DES for the treat...

Second versus first generation drug eluting stents during stent overexpansion.

Drug-eluting stents: the next generation

The small but absolute increase in late and very late stent thrombosis associated with drug-eluting stent technology may in part be related to the permanent, durable polymers currently employed with these stent platforms. Research has recently focused on two strategies to combat this problem; bioabsorbable polymers and polymer-free stents. This article critically reviews the key clinical trials...

Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.

OBJECTIVES This study sought to compare the risk of stent thrombosis among patients treated with bare-metal stents (BMS), first-generation drug-eluting stents (G1-DES), and second-generation drug-eluting stents (G2-DES) for a period of 3 years. BACKGROUND In patients undergoing coronary stenting, there is a scarcity of long-term follow-up data on cohorts large enough to compare rates of stent...